Podcast Episodes
Back to SearchAddressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy
Episode 236
Although CAR-T cells have revolutionized the treatment of hematological malignancies, there are several important factors that must be addressed rega…
2 years, 7 months ago
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks
The treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-…
2 years, 7 months ago
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks
Episode 235
The treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-…
2 years, 7 months ago
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents
The treatment landscape of acute myeloid leukemia (AML) has transformed in recent years with the introduction of novel targeted agents, including FLT…
2 years, 7 months ago
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents
Episode 234
The treatment landscape of acute myeloid leukemia (AML) has transformed in recent years with the introduction of novel targeted agents, including FLT…
2 years, 7 months ago
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms which can be categorized into lower- and higher-risk disease (LR-M…
2 years, 7 months ago
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
Episode 233
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms which can be categorized into lower- and higher-risk disease (LR-M…
2 years, 7 months ago
Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine
In the last decade, the treatment landscape of thalassemia has been transformed with the introduction of novel therapies. With several agents being e…
2 years, 8 months ago
Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine
Episode 232
In the last decade, the treatment landscape of thalassemia has been transformed with the introduction of novel therapies. With several agents being e…
2 years, 8 months ago
Updates, challenges and novel agents being explored in BPDCN
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy associated with poor prognosis. Several chall…
2 years, 8 months ago